Clinical Trial Update: Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the addition of ipilimumab to isolated limb infusion with melphalan and dactinomycin for advanced unresectable melanoma of the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dactinomycin (dactinomycin)
• Melphalan (Melphalan)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2018-05-15